Filing Flows › Harvard Bioscience (HBIO) › Q2 2026 › vs Q2 2025
Harvard Bioscience (HBIO) Q2 2026 vs Q2 2025 (year over year)
Harvard Bioscience's revenue rose $2.3M (+11%) from $20.4M in Q2 2025 to $22.7M in Q2 2026. The biggest changes: Instruments, Equipment, Software, and Accessories +$2.1M (+12%); Service, Maintenance, and Warranty Contracts +$151K (+7%).
Harvard Bioscience, Q2 2026: revenue $22.7M (+11% year over year), operating margin -4.3%, net loss $2.9M, operating cash flow $325K. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Instruments, Equipment, Software, and Accessories | $20.3M | $18.2M | $2.1M | +12% |
| Service, Maintenance, and Warranty Contracts | $2.4M | $2.3M | $151K | +7% |
| Revenue | $22.7M | $20.4M | $2.3M | +11% |
| Net loss | $2.9M | $2.3M | $628K | +28% |
| Costs & expenses | $25.6M | $22.7M | $2.9M | +13% |
| Operating costs | $23.7M | $21.3M | $2.4M | +11% |
| Interest & other, net | $1.9M | $1.4M | $483K | +34% |
| Income tax | $14K | $28K | −$14K | -50% |
| Cost of revenue | $10.1M | $8.9M | $1.2M | +13% |
| Research & development | $2.5M | $2.2M | $264K | +12% |
| Sales & marketing | $5.4M | $4.5M | $861K | +19% |
| General & admin | $4.6M | $4.3M | $355K | +8% |
| Other operating costs | $1.1M | $1.4M | −$224K | -16% |
| Operating cash sources | $3.2M | $5.0M | −$1.8M | -36% |
| Depreciation & amortization | $1.3M | $1.6M | −$286K | -18% |
| Share-based compensation | $380K | $472K | −$92K | -19% |
| Working capital & other | $1.6M | $3.0M | −$1.4M | -48% |
| Net loss absorbed | $2.9M | $2.3M | $628K | +28% |
| Operating cash flow | $325K | $2.8M | −$2.4M | -88% |
| Capital expenditures | $688K | $89K | $599K | +673% |
| Negative free cash flow (OCF − capex) | $363K | −$2.7M | $3.0M | — |
Questions
How much did Harvard Bioscience's revenue grow year over year in Q2 2026?
Harvard Bioscience's revenue rose $2.3M (+11%) from $20.4M in Q2 2025 to $22.7M in Q2 2026.
What drove Harvard Bioscience's revenue change in Q2 2026?
Instruments, Equipment, Software, and Accessories +$2.1M (+12%); Service, Maintenance, and Warranty Contracts +$151K (+7%).